Physiomics plc (LSE:PYC) has completed an oversubscribed WRAP Retail Offer, generating gross proceeds of £223,279.48 through the issuance of 74,426,493 new ordinary shares priced in line with a previously announced placing. Combined with the placing, the retail offer forms part of a conditional fundraising totalling £673,279.36, involving the issue of 224,426,453 new shares, subject to shareholder approval and the admission of the shares to trading on AIM.
The company has outlined the expected timetable for the process, with a general meeting scheduled for 7 April 2026 and admission of the new ordinary shares to AIM anticipated on 8 April 2026. Once admitted, the shares issued under both the placing and the WRAP Retail Offer will rank pari passu with the existing ordinary shares, ensuring that new and current investors hold the same class of equity following completion of the fundraising.
Physiomics’ outlook remains constrained by ongoing financial challenges, including continued losses and persistent cash burn. These pressures are partly offset by a balance sheet with relatively low leverage and signs of modest improvement in the company’s share price trend. However, valuation metrics remain limited due to negative earnings and the absence of dividend support.
More about Physiomics
Physiomics plc is a UK-based life sciences company that provides modelling and simulation, biostatistics, data science and bioinformatics services to biotechnology and pharmaceutical clients. Using proprietary platforms such as its Virtual Tumour technology, the company supports drug development programmes from early discovery stages through clinical trials. Its client base includes organisations such as Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics and Cancer Research UK.
Leave a Reply